Ambu downgrades, will cut costs

The Danish medtech firm’s preliminary Q3 report for 2021/2022 announced a cost reduction program, which will affect staffing and is expected to yield DKK 250m (USD 34.1m) in annualized savings.

Photo: PR / Ambu

On Wednesday, Danish medtech firm Ambu announced preliminary financial figures from the third quarter of fiscal 2021/2022 – alongside a guidance downgrade for the full-year and a cost reduction program meant to result in DKK 250m (USD 34.1m) annualized savings.

Ambu generated DKK 1.1bn (USD 150.2m) in sales in the three-month period, booking an operating profit (EBIT before special items) of DKK 42m (USD 5.7m). Organic growth amounted to 6% in July, which Ambu notes is ”significantly below [the firm’s] expectations.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs